

ERYTHROCYTES REDUCED GLUTATHIONE AND ERYTHROCYTE L- CYSTEINE INFLUX IN WILSON DISEASE

Kavita Priyadarshani¹, Suman Kumar Singh¹, Nayana Deb², Madhu Sinha³

Received : 11/03/2024
Received in revised form : 06/05/2024
Accepted : 22/05/2024

Keywords:

Human erythrocyte, L-Cysteine/L-cystine influx, reduced glutathione, Wilson's disease.

Corresponding Author:

Dr. Nayana Deb,
Email: nayana0409@yahoo.co.in

DOI: 10.47009/jamp.2024.6.3.34

Source of Support: Nil,
Conflict of Interest: None declared

Int J Acad Med Pharm
2024; 6 (3); 153-156



¹Tutor, Department of Biochemistry, PMCH, Patna, Bihar, India

²Assistant Professor, Department of Biochemistry, PMCH, Patna, Bihar, India

³Professor and HOD, Department of Biochemistry, PMCH, Patna, Bihar, India

Abstract

Background: Keeping this background in mind, the aim of the current study is to find out whether, in Wilson disease, L-cysteine/ L-cystine influx in RBC is decreased by high concentration of copper or not and the specific receptor responsible for this phenomenon. **Materials and Methods:** For L-cysteine/L-cystine influx, ten untreated cases, ten treated cases and ten age and sex matched healthy controls were recruited. To study the effect of copper on L-cysteine/L-cystine influx in RBC, 15 healthy subjects were selected. RBC GSH and L-cysteine/L-cystine influx were estimated by Beutler's and Yildiz's method respectively. **Result:** In untreated cases, L-cysteine/L-cystine influx and erythrocyte GSH level were decreased showing that elevated level of free copper in serum or media decreased L-cysteine/L-cystine influx in human RBC. Copper treatment inhibited L amino acid transporter in normal RBC specifically. **Conclusion:** In Wilson disease, free non-ceruloplasmin serum copper level is high which inhibits the L-cysteine/L-cystine uptake in RBC of untreated patients of Wilson disease.

INTRODUCTION

Wilson's disease is an autosomal recessive disease affecting ATP7B gene.^[1] In this disease copper is not excreted in the bile and it accumulates in brain, kidney, liver and RBC resulting in copper toxicosis.^[2] The frequency of Wilson's disease is about 1 in 30,000-40,000. The frequency of carriers of ATP7B gene's mutation is about 1 %. An affected patient's sibling has 1 in 4 risks.^[3] There are more than 200 mutations known.^[4] The disease may present with hepatic (at early/late teens); neuropsychiatric manifestations (typically in early twenties), or with hemolytic anaemia.^[3] In Wilson disease, serum ceruloplasmin level is low (90 % of cases),^[5] 24 h urinary copper excretion is elevated (usually >100 micro g/day) along with increased copper level per gram of dry weight of liver tissue (>200 micro g/gm).^[6,7] Though total serum copper level decreases as copper is mostly bound to ceruloplasmin, there is increased "free non-ceruloplasmin copper" in serum as well as in tissues.^[8] Pathogenesis is due to oxidant tissue injury induced by free copper.^[3] Increased free radical production by elevated plasma free copper through transition metal catalyzed Fenton reaction leads to oxidative stress induced injury, resulting in altered metabolism and severely compromised antioxidant status in RBC, hepatocytes and other

tissues, particularly in acute phases characterized by hemolysis.^[9] Previous studies showed that presence of excess copper ions led to the lower level of GSH concentration and G-6PD activity in erythrocytes.^[10,11] There is decrease in other RBC antioxidant parameters like superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, resulting in increased lipid per oxidation. Similarly, sulfhydryl groups and a- tocopherol showed the significant decline in their study. To combat free radical injury, GSH along with other enzymes and antioxidants is necessary.^[12] Synthesis of GSH is dependent upon supply of L-cysteine.^[13] The rate limiting step of GSH Synthesis is incorporation of L-cysteine to L-glutamate to form c glutamyl-L-cysteine.^[14] Almost all plasma cysteine exists as cystine. Cystine, the oxidized form of cysteine is transported in the cells via sodium independent transporter.^[15] In human RBC, Lcysteine is transported by both specific sodium dependent (ASC System) and nonspecific but large capacity sodium independent system (L-transporter). L-transporter system is less susceptible to inhibition by competing substrates at plasma levels.^[16] Keeping this background in mind, the aim of the current study is to find out whether, in Wilson disease, L-cysteine/ L-cystine influx in RBC is decreased by high concentration of copper or not and the specific receptor responsible for this phenomenon.

MATERIALS AND METHODS

To study the effect of copper on L-cysteine/L-cystine influx in RBC, 20 healthy subjects were selected. For L-cysteine/L-cystine influx, ten untreated cases, ten treated cases and ten age and sex matched healthy controls were recruited. The protocol was approved by institutional ethics committee of Patna Medical College. Proper informed consent was taken from every participant. Study was conducted in the department of Biochemistry, Patna Medical College from May 2022 to January 2023. Heparinized blood (10 U/ml) was collected aseptically from antecubital veins from each subject. The blood was centrifuged at 4 °C for 5 min at 2555×g, and the plasma and buffy coat were discarded. RBC was washed thrice with ice cold 0.9 % normal saline and was made to 50 % hematocrit in phosphate buffered saline (pH 7.4, prepared by mixing equal volume of 150 mM sodium phosphate buffer, pH 7.4 and 0.9 %, NaCl) containing 10 mM D-glucose and was used for studying L-cysteine transport (both through ASC system & Transporter L) & reduced glutathione level in RBC. As in our study there was no way to distinguish between L-cysteine influx and L-cystine influx in RBC through transporter L, we assigned the process as L-cysteine/L-cystine influx.

Plasma fasting glucose, bilirubin (total and direct), total protein, albumin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase estimation was performed on Erba-Mannheim, XL-600 autoanalyser. Total count of RBC, PCV (Packed cell volume), MCV (mean corpuscular volume) and MCHC (mean corpuscular hemoglobin Concentration) were estimated using automated cell counter (Sysmax, KX-21).

Serum ceruloplasmin was measured by Ravin's method.^[17] Serum copper and 24 h urinary copper were measured by the method of Abe et al,^[18] using

the color reagent 4(3, 5-dibromo-2 pyridylazo) N-ethyl-N-sulfopropylaniline. Erythrocyte GSH was estimated using the method of Beutler et al.^[19] Erythrocyte L-cysteine influx was measured by the method of Yildiz et al. using 10 mM L-cysteine hydrochloride.^[20] This concentration of L-cysteine hydrochloride was also used by Rizvi and Maurya,^[13] and Kumar and Maurya.^[21] RBC L-cysteine influx was expressed as $\mu\text{M}/\text{gm Hb}/\text{Hr}$. For copper induced inhibition of L-cysteine/L-cystine influx, RBC suspension (final concentration 25%) was incubated initially with 20 μM copper for 2 h prior to L-cysteine/L-cystine influx in erythrocytes. Hemoglobin was estimated by cyanmethemoglobin method.^[22] Erythrocyte GSH was also expressed in terms of $\mu\text{M}/\text{gm Hb}$.

Statistical Analysis: The results were expressed as mean \pm SD across the three study groups. Comparison for significance of difference between their mean values was done by analysis of variance (ANOVA) test using the Statistical Package for Social Sciences (SPSS) version 16 for windows programme. Multiple linear regression analyses were performed to show predictive values of serum ceruloplasmin, serum copper levels and RBC L-cysteine/L-cystine uptake on RBC GSH levels in both treated and untreated cases as well as in controls. p value <0.05 was considered to be statistically significant.

RESULTS

In this study, it was also observed that in treated cases and control groups the GSH concentration in RBC was not significantly dependent on L-cysteine/L-cystine uptake rate in RBC, serum copper concentration and serum ceruloplasmin concentration [Table 3].

Table 1: Inter group comparison of physical and clinical parameters

Parameters	Mean \pm SD			p* value		
	Controls	New cases	Treated cases	Controls versus new cases	Controls versus treated cases	New cases versus treated cases
Age (years)	28.0 \pm 9.77	18.9 \pm 7.87	26.0 \pm 6.26	>0.05	>0.05	>0.05
Sex (male/female)	5/5	5/6	6/5			
Serum ceruloplasmin (mg/dL)	27.67 \pm 9.55	18.19 \pm 5.3	16.3 \pm 4.30	<0.05	<0.05	>0.05
Serum copper $\mu\text{g}/\text{dL}$	92.13 \pm 12.19	43.83 \pm 9.48	46.03 \pm 7.12	<0.05	<0.05	>0.05
Urinary copper ($\mu\text{g}/\text{day}$)	54.04 \pm 29.22	327.9 \pm 138.61	142.8 \pm 47.23	<0.05	<0.05	>0.05

Table 2: Multiple comparisons by analysis of variance (ANOVA) with Bonferroni correction showing difference between control, new case and treated case groups regarding GSH concentration in RBC and rate of L-cysteine/L-cystine uptake by RBC

Dependent variable	Controls (0)	New cases (2)	Treated cases (3)	Mean Difference (I-J)	Sig. (p value)
RBC GSH concentration ($\mu\text{mol}/\text{g}$ of Hb)	9.15 \pm 0.67	6.07 \pm 0.26	9.09 \pm 0.77	1.66900 (0-1)	<0.001
				0.34100 (0-2)	0.641
				-4.31700 (1-2)	<0.001
RBC l-cysteine uptake rate ($\mu\text{mol}/\text{g}$ of Hb/hour)	12.16 \pm 2.40	5.68 \pm 0.47	13.02 \pm 0.27	6.46800 (0-1)	<0.001
				0.39900 (0-2)	0.169
				-7.334000 (1-2)	<0.001

Table 3: Multiple linear regression analysis to show predictive value of serum ceruloplasmin, RBC cysteine/cystine uptake rate and serum copper levels on RBC glutathione concentration in control, new case and treated case group

Constant	Controls Sig. (p value)	New Cases Sig. (p value)	Treated Cases Sig. (p value)
Ceruloplasmin	0.571	0.454	0.677
Serum copper	0.169	0.567	0.741
L-Cysteine uptake rate	0.071	0.051*	0.995

DISCUSSION

Experimental models performed by us showed the effect of negative effect of high copper (20 μ M) level upon RBC L-cysteine/L-cystine uptake of healthy human individuals. It was also found that the L-transporter system is primarily responsible for L-cysteine/L-cystine uptake in RBC compared to the ACS system. By altering buffer composition, it has been shown that it is the L-transporter (but not the ASC system) that is affected by copper (20 μ M) treatment. While studying the mechanism of action of the copper inhibition of L-cysteine/L-cystine uptake by L-transporter, we found in the literature that both in vitro and in vivo, CuSO₄ reduced the activity of 12 O tetradecanoylphorbol 13 acetate (TPA) stimulated protein kinase C suggesting inhibition of protein kinase C may be due to free copper ions.^[23] Since L-transporter activity is activated by protein kinase C,^[24] copper inhibition of L-transporter may be responsible for inhibition of L-cysteine/L-cystine uptake via L-transporter in presence of copper (20 μ M).

In vitro, extracellular cystine at 1.0 mM sustained GSH synthesis in GSH depleted RBCs only at the rate of 20 % of the maximum rate obtained with L-cysteine.^[25] This finding suggests that cysteine is a better candidate for GSH synthesis than cystine. The concentration of L-cysteine in plasma is in about 10 μ M.^[26] Since cysteine is transported in the RBCs also by high capacity, low affinity L-transport system, L-transporter would be expected to have considerable effect at the higher concentration of amino acid used experimentally. Non physiological extracellular concentration of L-cysteine estimates accumulation capacity of this amino acid in intact human RBC. Closs et al,^[27] used this approach. They obtained surprising data on the accumulation capacity of marine cationic amino acid transporters (mCAT—1, mCAT—2, mCAT—2a) in *Xenopus laevis* monocytes at a nonphysiological extracellular concentration of 10 mM L-arginine. Incubation of oocysts in 10 mM arginine for 6 h led to accumulation of arginine to the level of 0.6, 1.4 and 6 folds in mCAT—1, mCAT—2 and mCAT—2a expressing oocysts respectively.

Serum free copper level is high in Wilson's disease. The normal free copper value of serum is 1.6-2.4 μ mol/l and in untreated disease, it is often very high as 7.9 μ mol/l.^[3] Furthermore, the increased copper level in the liver cells appears to inhibit the binding of copper to apoceruloplasmin and leads to low level of ceruloplasmin in plasma.^[2] This high free copper produces inhibition of L-cysteine uptake by L-transporter of RBC in Wilson disease. To the best of

our knowledge, this is the first report of diminished L-cysteine influx in human RBC in Wilson disease. Also as RBC GSH level was low, decreased uptake of L-cysteine in human erythrocytes may affect intracellular synthesis of GSH. Rizvi and Maurya,^[13] had concluded that since glutathione synthesis in erythrocytes is dependent on the availability of L-cysteine, the decreased influx of L-cysteine in human erythrocytes during human aging may be a factor contributing to low GSH concentration. Similar phenomenon may occur in human RBCs in Wilson disease. This can further aggravate oxidative stress induced by Fenton reaction. That RBC GSH level is also dependent upon L-cysteine/L-cystine uptake was also evident from multiple linear regressions in untreated patients of Wilson disease [Table 3].

Reduced glutathione concentration as well as rate of L-cysteine/L-cystine uptake in erythrocytes, improved significantly in treated cases in comparison to new cases. There were no significant differences regarding these parameters between treated cases and controls.

The dependency of erythrocyte GSH concentration upon the L-cysteine/L-cystine uptake was no more present in treated cases. This was probably because after treatment, the regeneration of GSH was restored and consumption of GSH by free radicals and copper ions was reduced along with improved L-cysteine uptake.

CONCLUSION

20 μ M copper inhibits L-cysteine/L-cystine uptake in human RBC by inhibiting the amino acid transporter L. In Wilson disease, free non-ceruloplasmin serum copper level is high which inhibits the L-cysteine/L-cystine uptake in RBC of untreated patients of Wilson disease. Also in the untreated patients of Wilson disease, GSH concentration in RBC is low and is significantly dependent on the L-cysteine/L-cystine uptake in RBC.

REFERENCES

1. Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. *Nat Genet.* 1993;5(4):338–343. doi: 10.1038/ng1293-338. [PubMed] [CrossRef] [Google Scholar]
2. Murray RK. Plasma proteins and immunoglobulins. In: Murray RK, Bender DA, Botham KM, Kennly PJ, Rodwell VW, Weil PA, editors. *Harper's illustrated biochemistry.* New York: McGraw-Hill; 2009. pp. 566–592. [Google Scholar]
3. Brewer GJ, et al. Wilson disease. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, et al., editors. *Harrison's principles of internal medicine.* New York: McGraw-Hill; 2008. pp. 2449–2452. [Google Scholar]

4. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. *Nat Genet.* 1995;9(2):210–217. doi: 10.1038/ng0295-210. [PubMed] [CrossRef] [Google Scholar]
5. Sternlieb I, Giblin D, Scheinberg IH. Wilson disease. Marsden CD, Fahn S, editors. London: Butterworths; 1987.
6. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. *Medicine (Baltimore)* 1992;71(3):139–164. doi: 10.1097/00005792-199205000-00004. [PubMed] [CrossRef] [Google Scholar]
7. Fletcher N. Brain's disease of the nervous system. In: Donaghy M, editor. *Movement disorders.* Oxford: Oxford University Press; 2009. pp. 1233–1323. [Google Scholar]
8. Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. *Ann Intern Med.* 1991;115(9):720–726. doi: 10.7326/0003-4819-115-9-720. [PubMed] [CrossRef] [Google Scholar]
9. Forman SJ, Kumar KS, Redeker AG, Hochstein P. Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms. *Am J Hematol.* 1980;9(3):269–275. doi: 10.1002/ajh.2830090305. [PubMed] [CrossRef] [Google Scholar]
10. Metz EN. Mechanism of hemolysis by excess copper. *Clin Res.* 1969;17–32.
11. Deiss A, Lee GR, Cartwright GE. Hemolytic anemia in Wilson's disease. *Ann Intern Med.* 1970;73(3):413–418. doi: 10.7326/0003-4819-73-3-413. [PubMed] [CrossRef] [Google Scholar]
12. Steinebach OM, Wolterbeek HT. Role of cytosolic copper, metallothionein and glutathione in copper toxicity in rat hepatoma tissue culture cells. *Toxicology.* 1994;92(1–3):75–90. doi: 10.1016/0300-483X(94)90168-6. [PubMed] [CrossRef] [Google Scholar]
13. Rizvi SI, Maurya PK. L-cysteine influx in erythrocytes as a function of human age. *Rejuvenation Res.* 2008;11(3):661–665. doi: 10.1089/rej.2007.0652. [PubMed] [CrossRef] [Google Scholar]
14. Meister A, Anderson ME. Glutathione. *Annu Rev Biochem.* 1983;52:711–760. doi: 10.1146/annurev.bi.52.070183.003431. [PubMed] [CrossRef] [Google Scholar]
15. Bannai S, Christensen HN, Vadgama JV, Ellory JC, Englesberg E, Guidotti GG, et al. Amino acid transport systems. *Nature.* 1984;311(5984):308. [PubMed] [Google Scholar]
16. Ellory JC, Swietach P, Gibson JS. Amino acid transport. In: Bernhardt I, Ellory JC, editors. *Red cell membrane transport in health and disease.* Heidelberg: Springer-Verlag; 2003. pp. 303–319. [Google Scholar]
17. Ravin HA. An improved colorimetric enzymatic assay of ceruloplasmin. *J Lab Clin Med.* 1961;58:161–168. [PubMed] [Google Scholar]
18. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. *Clin Chem.* 1989;35(4):552–554. [PubMed] [Google Scholar]
19. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med.* 1963;61:882–888. [PubMed] [Google Scholar]
20. Yildiz D, Uslu C, Cakir Y, Oztas H. L-Cysteine influx and efflux: a possible role for red blood cells in regulation of redox status of the plasma. *Free Radic Res.* 2006;40(5):507–512. doi: 10.1080/10715760600602902. [PubMed] [CrossRef] [Google Scholar]
21. Kumar P, Maurya PK. L-Cysteine efflux in erythrocytes as a function of human age: correlation with reduced glutathione and total anti-oxidant potential. *Rejuvenation Res.* 2013;16(3):179–184. doi: 10.1089/rej.2012.1394. [PubMed] [CrossRef] [Google Scholar]
22. Zijlstra WG, van Kampen EJ. Standardization of hemoglobinometry. I. The extinction coefficient of hemiglobincyanide. *Clin Chim Acta.* 1960;5:719–726. doi: 10.1016/0009-8981(60)90014-0. [PubMed] [CrossRef] [Google Scholar]
23. Nilsson K. Effects of Cu(II) (3,5-diisopropylsalicylate)₂ on soluble protein kinase C activity in rat liver. *Cancer Lett.* 1989;47(3):169–177. doi: 10.1016/0304-3835(89)90087-6. [PubMed] [CrossRef] [Google Scholar]
24. Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. *Physiol Rev.* 2021;78(4):969–1054. [PubMed] [Google Scholar]
25. Whillier S, Raftos JE, Chapman B, Kuchel PW. Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. *Redox Rep.* 2022;14(3):115–124. doi: 10.1179/135100009X392539. [PubMed] [CrossRef] [Google Scholar]
26. Andersson A, Lindgren A, Arnadottir M, Prytz H, Hultberg B. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. *Clin Chem.* 2023;45(7):1084–1086. [PubMed] [Google Scholar]
27. Closs EI, Lyons CR, Kelly C, Cunningham JM. Characterization of the third member of the MCAT family of cationic amino acid transporters. Identification of a domain that determines the transport properties of the MCAT proteins. *J Biol Chem.* 2024;268(28):20796–20800. [PubMed] [Google Scholar]